Pacira BioSciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pacira BioSciences generated cash of $154,649,000, which is more than the previous year. Cash used in financing activities reached the amount of -$183,031,000 last year. Net change in cash is therefore $49,159,000.
Cash Flow
| 2014 | 25.46M | -119.33M | 118.87M |
|---|---|---|---|
| 2015 | 28.99M | -20.23M | 10.69M |
| 2016 | 33.45M | -61.75M | 7.26M |
| 2017 | 17.78M | -223.76M | 224.16M |
| 2018 | 48.87M | 20.57M | 8.95M |
| 2019 | 70.52M | -128.48M | 3.67M |
| 2020 | 77.03M | -277.60M | 222.30M |
| 2021 | 125.71M | -20.79M | 380.69M |
| 2022 | 145.27M | -225.18M | -401.52M |
| 2023 | 154.64M | 77.54M | -183.03M |
PCRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 104.13M | 585.57M | 99.95M | 78.22M | 132.52M | 54.12M | 35.94M | 56.98M | 37.52M | 12.51M |
Operating activities | ||||||||||
Net income | 41.95M | 15.90M | 41.98M | 145.52M | -11.01M | -471K | -42.61M | -37.94M | 1.85M | -13.71M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 75.57M | 91.50M | 28.54M | 19.90M | 19.57M | 13.16M | 13.83M | 12.91M | 11.47M | 10.03M |
Stock-based compensation expense | 47.89M | 48.09M | 42.24M | 39.92M | 33.65M | 0 | 31.60M | 31.24M | 33.36M | 24.82M |
| Deferred income tax benefit | 47.89M | 48.09M | 42.24M | 39.92M | 33.65M | 0 | 31.60M | 31.24M | 33.36M | 24.82M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -7.15M | -2.07M | -10.43M | -5.51M | -8.52M | -5.99M | -1.72M | -4.08M | -3.48M | -7.77M |
Inventories | -8.28M | 2.48M | -4.46M | -6.35M | -8.02M | -7.15M | -10.13M | 30.36M | -32.38M | -13.70M |
Accounts payable | 916K | 6.27M | -10.26M | -3.31M | -1.82M | -573K | 12.83M | -2.58M | 9.94M | 14.25M |
Cash generated by operating activities | 154.64M | 145.27M | 125.71M | 77.03M | 70.52M | 48.87M | 17.78M | 33.45M | 28.99M | 25.46M |
Investing activities | ||||||||||
Purchases Of Investments | -144.36M | -400.68M | -611.48M | -546.51M | -318.48M | -363.25M | -502.75M | -192.81M | -189.08M | -164.30M |
Investments In Property Plant And Equipment | -15.16M | -30.07M | -45.86M | -37.80M | -10.15M | -14.51M | -19.26M | -24.70M | -41.27M | -21.88M |
Acquisitions Net | 0 | -32M | -437.22M | -1.16M | -119.31M | -7M | -15M | -16M | -7M | -13M |
Cash generated by investing activities | 77.54M | -225.18M | -20.79M | -277.60M | -128.48M | 20.57M | -223.76M | -61.75M | -20.23M | -119.33M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 27.34M | 26.65M | 47.76M | 10.87M | 8.95M | 120.96M | 7.26M | 3.92M | 110.45M |
Payments for dividends | 0 | 0 | 0 | 0 | -4.31M | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -106K | 2.95M | 0 | -33.08M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -180.76M | -427.69M | -359.20M | -209.88M | -338K | 0 | 226.80M | -4K | -1.46M | 0 |
Cash used in financing activities | -183.03M | -401.52M | 380.69M | 222.30M | 3.67M | 8.95M | 224.16M | 7.26M | 10.69M | 118.87M |
Net Change In Cash | 49.15M | -481.43M | 485.62M | 21.72M | -54.29M | 78.4M | 18.18M | -21.04M | 19.46M | 25.00M |
Cash at end of period | 153.29M | 104.13M | 585.57M | 99.95M | 78.22M | 132.52M | 54.12M | 35.94M | 56.98M | 37.52M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |